136 related articles for article (PubMed ID: 38164873)
1. The role of tapentadol in cancer pain pharmacotherapy in patients with metastatic malignant disease.
Krtinic D; Nedin Rankovic G; Petkovic I; Cvetanovic A; Conic I; Todorovic Mitic M; Radic M; Milijasevic B; Lucic Prokin A; Djordjevic V; Jovanovic H; Trajkovic H; Andjelkovic Apostolovic M; Milijasevic D; Zdravkovic R; Binic I
Eur Rev Med Pharmacol Sci; 2023 Dec; 27(24):12112-12120. PubMed ID: 38164873
[TBL] [Abstract][Full Text] [Related]
2. Effectiveness and safety of tapentadol prolonged release for severe, chronic low back pain with or without a neuropathic pain component: results of an open-label, phase 3b study.
Steigerwald I; Müller M; Davies A; Samper D; Sabatowski R; Baron R; Rozenberg S; Szczepanska-Szerej A; Gatti A; Kress HG
Curr Med Res Opin; 2012 Jun; 28(6):911-36. PubMed ID: 22443293
[TBL] [Abstract][Full Text] [Related]
3. Effectiveness of Tapentadol Prolonged Release (PR) Compared with Oxycodone/Naloxone PR for the Management of Severe Chronic Low Back Pain with a Neuropathic Component: A Randomized, Controlled, Open-Label, Phase 3b/4 Study.
Baron R; Likar R; Martin-Mola E; Blanco FJ; Kennes L; Müller M; Falke D; Steigerwald I
Pain Pract; 2016 Jun; 16(5):580-99. PubMed ID: 26095455
[TBL] [Abstract][Full Text] [Related]
4. Tapentadol prolonged release versus strong opioids for severe, chronic low back pain: results of an open-label, phase 3b study.
Gálvez R; Schäfer M; Hans G; Falke D; Steigerwald I
Adv Ther; 2013 Mar; 30(3):229-59. PubMed ID: 23475406
[TBL] [Abstract][Full Text] [Related]
5. Tolerability, Safety, and Quality of Life with Tapentadol Prolonged Release (PR) Compared with Oxycodone/Naloxone PR in Patients with Severe Chronic Low Back Pain with a Neuropathic Component: A Randomized, Controlled, Open-label, Phase 3b/4 Trial.
Baron R; Jansen JP; Binder A; Pombo-Suarez M; Kennes L; Müller M; Falke D; Steigerwald I
Pain Pract; 2016 Jun; 16(5):600-19. PubMed ID: 26554630
[TBL] [Abstract][Full Text] [Related]
6. Effectiveness and Safety of Tapentadol Prolonged Release (PR) Versus a Combination of Tapentadol PR and Pregabalin for the Management of Severe, Chronic Low Back Pain With a Neuropathic Component: A Randomized, Double-blind, Phase 3b Study.
Baron R; Martin-Mola E; Müller M; Dubois C; Falke D; Steigerwald I
Pain Pract; 2015 Jun; 15(5):455-70. PubMed ID: 24738609
[TBL] [Abstract][Full Text] [Related]
7. A prospective, multicenter, open-label study of the clinical efficacy of tapentadol extended-release in the treatment of cancer-related pain and improvement in the quality of life of opioid-naïve or opioid-resistant patients.
Jung JY; Chon HJ; Choi YJ; Yeon SE; Choi SY; Lee KH
Support Care Cancer; 2022 Jul; 30(7):6103-6112. PubMed ID: 35420330
[TBL] [Abstract][Full Text] [Related]
8. Effectiveness and Tolerability of a Moderate Dose of Tapentadol Prolonged Release for Managing Severe, Chronic Low Back Pain with a Neuropathic Component: An Open-label Continuation Arm of a Randomized Phase 3b Study.
Baron R; Kern U; Müller M; Dubois C; Falke D; Steigerwald I
Pain Pract; 2015 Jun; 15(5):471-86. PubMed ID: 24750558
[TBL] [Abstract][Full Text] [Related]
9. Direct conversion from tramadol to tapentadol prolonged release for moderate to severe, chronic malignant tumour-related pain.
Kress HG; Koch ED; Kosturski H; Steup A; Karcher K; Dogan C; Etropolski M; Eerdekens M
Eur J Pain; 2016 Oct; 20(9):1513-8. PubMed ID: 27062079
[TBL] [Abstract][Full Text] [Related]
10. Tapentadol prolonged release for managing moderate to severe, chronic malignant tumor-related pain.
Kress HG; Koch ED; Kosturski H; Steup A; Karcher K; Lange B; Dogan C; Etropolski MS; Eerdekens M
Pain Physician; 2014; 17(4):329-43. PubMed ID: 25054392
[TBL] [Abstract][Full Text] [Related]
11. Tapentadol prolonged release in patients with chronic low back pain: real-world data from the German Pain eRegistry.
Überall MA; Elling C; Eibl C; Müller-Schwefe GH; Lefeber C; Heine M; Heckes B
Pain Manag; 2022 Mar; 12(2):211-227. PubMed ID: 34376059
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of tapentadol prolonged release for pre- and post-operative low back pain: a prospective observational study.
Bagaphou TC; Cerotto V; Gori F
Eur Rev Med Pharmacol Sci; 2019 Nov; 23(4 Suppl):14-20. PubMed ID: 31755078
[TBL] [Abstract][Full Text] [Related]
13. Ready conversion of patients with well-controlled, moderate to severe, chronic malignant tumor-related pain on other opioids to tapentadol extended release.
Imanaka K; Tominaga Y; Etropolski M; Ohashi H; Hirose K; Matsumura T
Clin Drug Investig; 2014 Jul; 34(7):501-11. PubMed ID: 24906437
[TBL] [Abstract][Full Text] [Related]
14. [Tapentadol prolonged release for severe chronic pain. Results of a non-interventional study involving general practitioners and internists].
Schwittay A; Schumann C; Litzenburger BC; Schwenke K
MMW Fortschr Med; 2012 Oct; 154 Suppl 3():85-93. PubMed ID: 23133884
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of tapentadol for first-line opioid-resistant neuropathic pain in Japan.
Sugiyama Y; Kataoka T; Tasaki Y; Kondo Y; Sato N; Naiki T; Sakamoto N; Akechi T; Kimura K
Jpn J Clin Oncol; 2018 Apr; 48(4):362-366. PubMed ID: 29506199
[TBL] [Abstract][Full Text] [Related]
16. Tapentadol for chronic musculoskeletal pain in adults.
Santos J; Alarcão J; Fareleira F; Vaz-Carneiro A; Costa J
Cochrane Database Syst Rev; 2015 May; 2015(5):CD009923. PubMed ID: 26017279
[TBL] [Abstract][Full Text] [Related]
17. Practical considerations for the use of tapentadol prolonged release for the management of severe chronic pain.
Sánchez Del Águila MJ; Schenk M; Kern KU; Drost T; Steigerwald I
Clin Ther; 2015 Jan; 37(1):94-113. PubMed ID: 25108647
[TBL] [Abstract][Full Text] [Related]
18. [Tapentadol prolonged release for the treatment of severe chronic tumor pain in routine clinical practice].
Agbalaka A; Schwenke K; Litzenburger B
MMW Fortschr Med; 2012 Dec; 154 Suppl 4():123-30. PubMed ID: 23326931
[TBL] [Abstract][Full Text] [Related]
19. Long-term, prolonged-release oral tapentadol for the treatment of refractory chronic low back pain: a single-center, observational study.
Finco G; Mura P; Musu M; Deidda C; Saba M; Demelas I; Evangelista M; Sardo S
Minerva Med; 2018 Aug; 109(4):259-265. PubMed ID: 29947490
[TBL] [Abstract][Full Text] [Related]
20. Tapentadol in Cancer Patients with Neuropathic Pain: A Comparison of Methadone, Oxycodone, Fentanyl, and Hydromorphone.
Takemura M; Niki K; Okamoto Y; Matsuda Y; Omae T; Takagi T; Ueda M
Biol Pharm Bull; 2021; 44(9):1286-1293. PubMed ID: 34471056
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
